In the survey of major unlisted startups in Japan by Nikkei BP, Innovacell ranks first in cumulative fundraising amount in the business field of ‘Regenerative Medicine Products.
We are pleased to announce that our company will be featured in the ‘Bio-Healthcare Startup Overview 2023-2024’ published by Nikkei BP on October 2, 2023. This overview includes 304 notable domestic bio-healthcare startups selected by the Nikkei Biotechnology editorial team.
Additionally, in conjunction with the publication of the Nikkei BP overview, some research results and unique analyses regarding the cumulative fundraising amounts and business sectors of major unlisted startups in the bio and healthcare fields have been released in a feature by Nikkei Biotechnology. According to this feature, Innovacell ranks first in cumulative fundraising in the regenerative medicine sector and second overall.
*The links in the text direct to the website of Nikkei Biotechnology, operated by Nikkei BP.
Innovacell will continue to work diligently on the Phase III international joint clinical trial of ICEF15 and the ongoing development of our pipeline products.
About ICEF15:
This product aims to treat urgent fecal incontinence by utilizing the patient’s own myoblasts and promoting muscle regeneration through “local administration.